市场调查报告书
商品编码
1466695
支架市场:按类型、材料、交付方式、最终用户划分 - 2024-2030 年全球预测Stents Market by Type (Coronary Stents, Peripheral Vascular Stents, Prostatic Stents), Material (Biomaterials, Metallic Stents), Mode of Delivery, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年支架市场规模为129.9亿美元,预计2024年将达到139.5亿美元,2030年将达到215.7亿美元,复合年增长率为7.51%。
支架被插入阻塞的途径中,以打开心臟中的途径,例如供应富氧血液的薄弱或狭窄的动脉。支架由塑胶或金属製成,并涂上药物,可防止阻塞的动脉闭合。与先进的 DES 和先进的生物可吸收支架的引入相比,留置技术比传统的球囊血管成形术越来越受青睐。由于心血管疾病盛行率的上升、老年人口的增加以及对微创手术的日益偏好,对支架的需求正在增加。然而,支架系统召回和与支架相关的风险的快速增加可能会对市场成长产生负面影响。另一方面,新支架设计的推出和监管机构产品核可预计将增加医疗机构对支架的采用。
主要市场统计 | |
---|---|
基准年[2023] | 129.9亿美元 |
预测年份 [2024] | 139.5亿美元 |
预测年份 [2030] | 215.7亿美元 |
复合年增长率(%) | 7.51% |
类型:全球范围内需要置入冠状动脉支架的冠状动脉疾病发生率较高
冠状动脉支架用于打开阻塞的心臟动脉,在冠状动脉疾病的治疗中发挥重要作用。这些支架因其微创性质而受到青睐,并大大改善了患者的治疗效果。裸金属支架由金属合金製成,可作为保持冠状动脉开放的支架。透过血管成形术将支架放入动脉后,支架周围的动脉会癒合,使其保持开放。药物释放型支架代表了支架技术的进步。这些支架涂有药物,该药物会缓慢释放(洗脱)到动脉壁中,以防止疤痕组织生长,从而血管再阻塞。 DES 显着降低了血管再阻塞的发生率和重复干预的需要,使其成为大多数支架置入置入术的首选。週边血管支架用于治疗周边动脉疾病(PAD)并针对心臟和大脑以外的动脉。对于控制四肢血流障碍和预防截肢至关重要。随着人口老化和 PAD 盛行率的增加,需求不断增长。前列腺支架主要用于缓解良性前列腺增生(BPH)引起的尿路阻塞。血管支架是一种侵入性较小的手术替代方案。血管支架用于血管内治疗,以治疗腹部或胸部区域的主动脉瘤。与开放性手术相比,血管支架因其恢復时间更快且併发症风险更低而成为首选的微创方法。泌尿系统支架用于在尿路阻塞时确保尿液通过。它对于肾结石和其他泌尿系统疾病的治疗至关重要。对泌尿器官系统支架的偏好是因为它们在预防和治疗肾衰竭方面的作用。
最终用户:在政府改善卫生基础设施努力的支持下,医院正在世界各地扩张。
门诊手术中心 (ASC) 是支架治疗的重要场所,通常提供门诊服务,重点是择期手术。 ASC 的特点是效率、成本效益以及为患者提供的便利。 ASC 主要处理较不复杂的冠状动脉和周边介入治疗。在这些情况下,首选轻量、易于部署且高精度的支架,以最大限度地减少手术和恢復时间。因此,药物释放型支架(DES)是 ASC 的首选,因为它们可以降低血管再阻塞的风险。心臟中心是专门从事心臟病诊断和治疗的专业机构。这些设施能够执行各种支架置入操作,包括需要先进基础设施(例如混合手术室)的复杂手术。这些中心需要多种支架置入选择,包括生物可吸收血管支架 (BVS) 和生物工程支架,以解决各种冠状动脉疾病。治疗分叉病变和慢性完全闭塞等复杂病例的能力极为重要。医院是最广泛的最终用户部门,具有广泛的功能。近年来,医院服务变得更加多样化,能够处理大量病例。由于支架的有效性、多功能性和成本效益,医院越来越青睐支架。此外,为了适应不同的患者群体,对支援各种血管尺寸和病变类型的支架的需求不断增长。
区域洞察
美洲支架市场的发展得益于成熟的知名製造商的存在,这些製造商提供多样化的支架产品组合,并不断升级其研发以满足医疗需求。近年来,美国食品药物管理局多次核准药物释放型和心臟支架,鼓励该地区进一步的支架创新。亚太地区是西方国家的主要原料来源地,主要由来自印度、中国和日本的可靠支架製造商主导。该国改善了心血管手术和支架使用的报销结构,各国政府正在努力为医疗机构提供具有成本效益的支架。在欧洲,由于安全措施和专注于引入生物分解性支架的研究工作,支架市场变得更加标准化。中东地区医疗基础设施投资大幅增加,成为市场相关人员业务扩张的潜在基地。
FPNV定位矩阵
FPNV定位矩阵对于评估支架市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对支架市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.支架市场的市场规模和预测是多少?
2.支架市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些?
3.支架市场的技术趋势和法规结构是什么?
4.支架市场主要厂商的市场占有率是多少?
5.进入支架市场合适的形式或策略手段是什么?
[194 Pages Report] The Stents Market size was estimated at USD 12.99 billion in 2023 and expected to reach USD 13.95 billion in 2024, at a CAGR 7.51% to reach USD 21.57 billion by 2030.
Stents are inserted into blocked passageways to open passages in the heart, such as weak or narrowed arteries providing oxygen-rich blood. Stents are made of either plastic or metal and are coated with drugs to help prevent blocked arteries from closing. Stenting technology is increasingly preferred over conventional balloon angioplasty due to the introduction of advanced DES and evolving bioresorbable scaffolds. The rising incidence of cardiovascular diseases, the expanding elderly population, and the increasing preference for minimally invasive procedures have created a need for the utilization of stents. However, the surging incidence of recalls of stent systems and the risk associated with the stents may adversely impact the market's growth. Moreover, introducing new stent designs and product approvals from regulatory authorities are expected to increase the adoption of stents by healthcare facilities.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 12.99 billion |
Estimated Year [2024] | USD 13.95 billion |
Forecast Year [2030] | USD 21.57 billion |
CAGR (%) | 7.51% |
Type: High global incidences of coronary diseases necessitating the deployment of coronary stents
Coronary stents are used in procedures to open clogged heart arteries, playing a critical role in the treatment of coronary heart diseases. These stents are preferred for their minimally invasive nature and the significant improvement in patient outcomes they offer. Bare-metal stents are made of a metal alloy and act as a scaffold to keep the coronary artery open. After the stent is placed in the artery during a procedure known as angioplasty, the artery heals around the stent, maintaining the artery in an open position. Drug-eluting stents represent an advancement in stent technology. These stents are coated with a medication that is slowly released (eluted) into the artery wall to prevent scar tissue growth and, subsequently, restenosis. DES have significantly reduced the incidences of restenosis and the need for repeat interventions, making them the preferred choice in most stenting procedures. Peripheral vascular stents serve to treat peripheral artery disease (PAD), targeting arteries outside the heart and brain. They are essential in managing blood flow obstruction in limbs and preventing amputations. With an aging population and rising PAD prevalence, the demand is growing. Prostatic stents are primarily used to provide relief from urinary obstruction caused by benign prostatic hyperplasia (BPH). Their preference stems from being a less invasive alternative to surgery for patients unable or unwilling to undergo traditional procedures. Stent grafts are used in endovascular procedures to treat abdominal and thoracic aortic aneurysms. They are preferred due to their minimally invasive approach, which reduces recovery time and risk of complications compared to open surgery. Urinary stents are employed to ensure the passage of urine in cases of obstructions in the urinary tract. They are crucial in the management of kidney stones and other urological conditions. The preference for urinary stents lies in their role in preventing or treating renal failure.
End-User: Expansion of hospitals across the world supported by government initiatives for improving healthcare infrastructure
Ambulatory surgical centers (ASCs) represent a critical setting for stent procedures, offering outpatient services that typically focus on elective surgeries. ASCs are characterized by their efficiency, cost-effectiveness, and the convenience they offer to patients. ASCs primarily deal with less complex coronary and peripheral interventions. The preference for lightweight, easy-to-deploy, and high-precision stents is essential in this environment to minimize operative and recovery time. This makes drug-eluting stents (DES) highly favored in ASCs for their reduced risk of restenosis. Cardiac centers are specialized facilities focused exclusively on the diagnosis and treatment of heart conditions. They are equipped to perform a diverse range of stent placements, including more complex procedures that require advanced infrastructural capabilities, such as hybrid operating rooms. There's a demand for versatile stenting options in these centers, including bioresorbable vascular scaffolds (BVS) and bio-engineered stents, to cater to a diverse range of coronary artery diseases. Capability in treating complex cases, such as bifurcation lesions or chronic total occlusions, is crucial. Hospitals represent the broadest end-user sector, encompassing a wide range of capabilities. The versatility of hospital services and their capacity to manage high-volume cases has grown in recent years. The preference in hospitals leans toward stents that offer a combination of efficacy, versatility, and cost-effectiveness. There is also a notable requirement for stents that support a broad range of vessel sizes and lesion types, accommodating the diverse patient demographic.
Regional Insights
The stent market in the Americas is advanced, driven by the presence of well-established and recognized manufacturers serving a diverse portfolio of stents and constantly upgrading their R&D to keep up with medical requirements. In the past few years, the U.S. Food & Drug Administration has provided multiple approvals for drug-eluting and cardiac stents, supporting further stent innovation in the region. The Asia-Pacific region is a mass provider of raw materials to Western nations and is occupied by trusted stent producers across India, China, and Japan. The country observes an improved reimbursement structure for heart surgeries and stent usage, and governments are working toward offering cost-effective stents to healthcare facilities. Europe has a more standardized stent market characterized by safety initiatives and research activities focused on introducing biodegradable stents. The Middle East region witnesses an exponential increase in investments in healthcare infrastructure advancements, creating the region a potential base for company expansion for market players.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Stents Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stents Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Stents Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alvimedica, Andramed GmbH, Arterius Limited, B. Braun SE, Balton Sp. z o. o., Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cardinal Health Inc., Cook Medical LLC, Elixir Medical Corporation, Eurocor Tech GmbH, Integer Holdings Corporation, KYOTO MEDICAL PLANNING Co., Ltd., Lepu Medical Technology(Beijing)Co., Ltd., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, Mitra Industries Pvt. Ltd., Nano Therapeutics Pvt. Ltd., QMD, REVA Medical, LLC, Rontis AG, Scitech Medical Products SA, SLTL Group, Stryker Corporation, Terumo Corporation, Veryan Medical Ltd., and W. L. Gore & Associates, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Stents Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stents Market?
3. What are the technology trends and regulatory frameworks in the Stents Market?
4. What is the market share of the leading vendors in the Stents Market?
5. Which modes and strategic moves are suitable for entering the Stents Market?
TABLE 4